Dr. Young joined Celldex in July 2019 as Senior Vice President and Chief Medical Officer. Prior to joining Celldex, she was the Chief Medical Officer of GTx, Inc., a public biopharmaceutical company focused on developing therapeutics that target nuclear hormone receptors. Previously, she spent 13 years at Novartis Oncology in senior leadership roles in global clinical development and medical affairs. As the Head of Oncology Clinical Development, she directed the clinical programs leading to successful regulatory approvals for EXJADE®, GLIVEC®, FEMARA®, AFINITOR®, RYDAPT®, JAKAVI® and FARIDAK® among others. Prior to Novartis, Diane held senior leadership positions in clinical development at the R.W. Johnson Pharmaceutical Research Institute of Johnson & Johnson, Hoffman-La Roche and Sandoz. Dr. Young received her A.B. in Biochemical Sciences at Harvard University and her M.D. from Harvard Medical School. Her postdoctoral training included an Internal Medicine Residency at Johns Hopkins Hospital and Vanderbilt Hospital, followed by an Oncology Fellowship at the Dana-Farber Cancer Institute. She is board certified in Internal Medicine and Medical Oncology.